Next-generation targeted
RNA delivery
A paradigm shift in RNA therapeutics. MOTE's platform expands the horizon of
RNA medicines by unlocking scalable, modular, cell-specific delivery.
Our Science
At MOTE, we innovate in targeted delivery. Our non-covalent surface functionalization technology enables scalable and modular targeting of a wide range of cell types.
Our mobilize TM Platform
Our core platform technology focuses on developing proprietary targeted LNPs (tLNPs) through a modular, simple and elegant process that circumvents the challenges associated with the conventional chemical surface functionalization approaches. A simple inline mixing allows tethering of a recombinant targeting ligand that postmarks the RNA containing LNPs to specific target tissues for a precision in vivo cell reprogramming.
Our Pipeline
We are building a portfolio of targeted RNA nanomedicines to address unmet medical needs in several therapeutic areas, including immune cell reprogramming, as well as treatments targeting CNS tissues and hematopoietic stem cells (HSCs).
| Target | Indication | Discovery | Preclinical | Phase I |
|---|---|---|---|---|
| T cells | Systemic lupus erythematosus (SLE) | |||
| HSC | Undisclosed | |||
| CNS | Undisclosed |
About Us
MOTE Therapeutics is an innovative preclinical-stage startup building the RNA medicines of tomorrow.
A Next-Gen RNA Delivery
Platform
MOTE Therapeutics is an innovative biotechnology startup. We are building the leading platform for targeted RNA delivery - unlocking new classes of therapeutics for tissues and cell types previously beyond reach.
mobilize, a noncovalent
functionalization platform
MOTE has developed a targeted LNP platform named mobilize for extrahepatic delivery of circRNA. The platform combines hepatic de -targeting with cell-specific ligand engineering.
Learn more about our news ＆ events
